FDA approves Lilly's Lartruvo for STS

FDA granted accelerated approval to Lartruvo olaratumab from Eli Lilly and Co. (NYSE:LLY) in combination with doxorubicin to treat advanced soft tissue sarcoma patients who cannot be cured with radiation or surgery and for whom chemotherapy is appropriate.

Lilly spokesperson Karen Glowacki told BioCentury that Lartruvo would be available "in the coming weeks," and that the company has not yet set the drug's price. ...